IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9834526 B1

PDFFull Text
Date of Patent:
Dec. 05, 2017

Filed:

Dec. 17, 2014

Hiv protease inhibitors

Applicants:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Merck Canada Inc., Kirkland, CA;

Inventors:

John A. McCauley, Maple Glen, PA (US);

Christian Beaulieu, Laval, CA;

David Jonathan Bennett, Boston, MA (US);

Christopher J. Bungard, Lansdale, PA (US);

Sheldon Crane, Ile Perrot, CA;

Thomas J. Greshock, Collegeville, PA (US);

Katharine M. Holloway, Lansdale, PA (US);

Daniel McKay, Ville St-Laurent, MA (US);

Carmela Molinaro, Rahway, NJ (US);

Oscar Miguel Moradei, Kirkland, CA;

Satyanarayana Tummanapalli, Singapore Science Park III, SG;

Vouy Linh Truong, Pierrefonds, CA;

Peter D. Williams, Harleysville, PA (US);

Assignees:

MERCK SHARP & DOHME CORP., Rahway, NJ (US);

MERCK CANADA INC., Kirkland, Quebec, CA;

Attorneys:

Carol S. Quagliato

Catherine D. Fitch

Primary Examiner:

Shengjun Wang

Int. Cl.
CPC ...
A61K 31/535 (2006.01); C07D 265/28 (2006.01); C07D 265/30 (2006.01); A61K 45/06 (2006.01); A61K 31/5375 (2006.01); A61K 31/5377 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 513/04 (2006.01);
U.S. Cl.
CPC ...
C07D 265/30 (2013.01); A61K 31/5375 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 513/04 (2013.01);
Abstract

The present invention is directed to 2,5,6-substituted morpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Find Patent Forward Citations

Loading…